Pirmitegravir

Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24,000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties[1].

Product Specifications

CAS Number

[2245231-10-9]

Product Name Alternative

STP0404

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

HIV; HIV Integrase

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/pirmitegravir.html

Purity

99.76

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C([C@H](C1=C(N=C(C2=C1C3=CC=C(C=C3)Cl)N(C(C)=C2C)CC4=CN(N=C4)C)C)OC(C)(C)C)O

Molecular Formula

C27H31ClN4O3

Molecular Weight

495.01

Precautions

H302, H315, H319

References & Citations

[1]Maehigashi T, et al. A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF/p75-integrase interaction site. PLoS Pathog. 2021;17 (7) :e1009671.